• S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

  • Nov 15 2023
  • Length: 32 mins
  • Podcast

S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

Listen for free

View show details

  • Summary

  • The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. 

    Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    Show More Show Less
Show More Show Less
activate_samplebutton_t1

What listeners say about S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.